OncoMatch/Clinical Trials/NCT06097728

MEDI5752 in Combination With Carboplatin Plus Pemetrexed in Unresectable Pleural Mesothelioma

Is NCT06097728 recruiting? Yes, currently enrolling (May 2026). This Phase 3 trial studies multiple treatments for unresectable pleural mesothelioma.

Phase 3RecruitingAstraZenecaNCT06097728Data as of May 2026

Treatment: Volrustomig · Pemetrexed · Carboplatin · Cisplatin · Nivolumab · Ipilimumab — This is a phase III, randomized, open-label, multicenter, global study to determine the efficacy and safety of Volrustomig (MEDI5752) + Carboplatin + Pemetrexed vs the investigator's choice of platinum + Pemetrexed or Nivolumab + Ipilimumab in participants with unresectable pleural mesothelioma.

Check if I qualify

Extracted eligibility criteria

Cancer type

Mesothelioma

Performance status

WHO/ECOG 0–1

Lab requirements

Blood counts

adequate bone marrow reserve at baseline

Kidney function

adequate organ function at baseline

Liver function

adequate organ function at baseline

Has adequate bone marrow reserve and organ function at baseline

Structured fields extracted by AI. May contain errors — verify against the official protocol.

US trial sites

Research Site · Phoenix, Arizona
Research Site · Duarte, California
Research Site · Santa Rosa, California
Research Site · Aurora, Colorado
Research Site · Jacksonville, Florida

Showing up to 5 US sites. See all sites on ClinicalTrials.gov →

Could you qualify for this trial?

Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.

Check if I qualify